Form D · Biotechnology
Antlia Bioscience, Inc.
Encinitas, CA · CIK 0001829522
Offering snapshot reported Jun 5, 2026 · SEC filing
- Reported sold
- $6M Offering amount: $20M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 22, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 5, 2026 | Initial | $6,000,000 | No comparison | 3 | SEC filing |
| Apr 26, 2022 | Initial | $680,000 | No comparison | 10 | SEC filing |
| Oct 23, 2020 | Initial | $207,000 | No comparison | 7 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-586295
Source: Form D, filed Jun 5, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ben Auspitz | Director |
| Carlos Garcia Echeverria | Director |
| Brian Laurence Johnson | Director, Executive |
| Ankit Mahadevia | Director, Executive |
| Nihal Sinha | Director |
| Martin Taylor | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1281 Hymettus Ave
Encinitas, CA, 92024
Encinitas, CA, 92024